Inflammatory mediator of ocular surface and lacrimal gland

Ocular surface/lacrimal gland inflammation mediators" is not a specific molecular target but rather refers to a **broad group of pro-inflammatory molecules**—primarily **cytokines** such as interleukin 6 (*IL‑6*), tumor necrosis factor alpha (*TNF‑α*), matrix metalloproteinases (*MMPs*, especially MMP‑9), nitric oxide, and others—that are upregulated during immune-mediated diseases affecting the ocular surface and lacrimal glands[1][3][4][6][7]. These mediators play central roles in the pathogenesis of conditions like dry eye disease and Sjögren’s syndrome by promoting tissue damage, altering epithelial function, recruiting immune cells, and perpetuating chronic inflammation[2][3][8]. They do not represent a single protein or receptor but encompass multiple signaling pathways involving both innate and adaptive immunity. As such, they are considered *pathogenic factors* or *biomarker panels*, not canonical drug targets themselves. Therapeutic strategies often aim to suppress their production or block their effects using broad immunomodulatory agents rather than targeting an individual molecule[5]. Because this entry does **not correspond to a unique molecular entity**, it is considered incorrect as a canonical therapeutic target name. Instead, for structured data purposes you should extract individual validated targets from this group—such as "Interleukin 6", "Tumor necrosis factor alpha", or "Matrix metalloproteinase 9"—for which all requested fields can be properly completed[1][4][7].

Other names

Ocular surface inflammatory mediatorsLacrimal gland inflammatory mediatorsProinflammatory cytokines (ocular)Inflammatory cytokines (lacrimal)

Immunosuppression of T-cell activation and cytokine release; Blockade of cell adhesion molecules involved in immune cell recruitment